Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elisabeth von Guggenberg, Petra Kolenc, Christof Rottenburger, Renata Mikołajczak, Alicja Hubalewska-Dydejczyk
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cholecystokinin-2 receptor agonist antagonist tumor targeting molecular imaging targeted radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/39929c74eb0f41469615cdf0f02b4031
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39929c74eb0f41469615cdf0f02b4031
record_format	dspace
spelling	oai:doaj.org-article:39929c74eb0f41469615cdf0f02b40312021-11-25T17:03:52ZUpdate on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals10.3390/cancers132257762072-6694https://doaj.org/article/39929c74eb0f41469615cdf0f02b40312021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5776https://doaj.org/toc/2072-6694The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development of CCK2R targeting compounds and the ongoing clinical trials are presented. Currently, new gastrin derivatives as well as nonpeptidic substances are being developed to improve the properties for clinical use. A team of specialists from the field of radiopharmacy and nuclear medicine reviewed the available literature and summarized their own experiences in the development and clinical testing of CCK2R targeting radiopharmaceuticals. The recent clinical trials with novel radiolabeled minigastrin analogs demonstrate the potential for both applications, imaging as well as targeted radiotherapy, and reinforce the clinical applicability within a theranostic concept. The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.Elisabeth von GuggenbergPetra KolencChristof RottenburgerRenata MikołajczakAlicja Hubalewska-DydejczykMDPI AGarticlecholecystokinin-2 receptoragonistantagonisttumor targetingmolecular imagingtargeted radiotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5776, p 5776 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cholecystokinin-2 receptor agonist antagonist tumor targeting molecular imaging targeted radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cholecystokinin-2 receptor agonist antagonist tumor targeting molecular imaging targeted radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Elisabeth von Guggenberg Petra Kolenc Christof Rottenburger Renata Mikołajczak Alicja Hubalewska-Dydejczyk Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
description	The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development of CCK2R targeting compounds and the ongoing clinical trials are presented. Currently, new gastrin derivatives as well as nonpeptidic substances are being developed to improve the properties for clinical use. A team of specialists from the field of radiopharmacy and nuclear medicine reviewed the available literature and summarized their own experiences in the development and clinical testing of CCK2R targeting radiopharmaceuticals. The recent clinical trials with novel radiolabeled minigastrin analogs demonstrate the potential for both applications, imaging as well as targeted radiotherapy, and reinforce the clinical applicability within a theranostic concept. The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.
format	article
author	Elisabeth von Guggenberg Petra Kolenc Christof Rottenburger Renata Mikołajczak Alicja Hubalewska-Dydejczyk
author_facet	Elisabeth von Guggenberg Petra Kolenc Christof Rottenburger Renata Mikołajczak Alicja Hubalewska-Dydejczyk
author_sort	Elisabeth von Guggenberg
title	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
title_short	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
title_full	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
title_fullStr	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
title_full_unstemmed	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
title_sort	update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/39929c74eb0f41469615cdf0f02b4031
work_keys_str_mv	AT elisabethvonguggenberg updateonpreclinicaldevelopmentandclinicaltranslationofcholecystokinin2receptortargetingradiopharmaceuticals AT petrakolenc updateonpreclinicaldevelopmentandclinicaltranslationofcholecystokinin2receptortargetingradiopharmaceuticals AT christofrottenburger updateonpreclinicaldevelopmentandclinicaltranslationofcholecystokinin2receptortargetingradiopharmaceuticals AT renatamikołajczak updateonpreclinicaldevelopmentandclinicaltranslationofcholecystokinin2receptortargetingradiopharmaceuticals AT alicjahubalewskadydejczyk updateonpreclinicaldevelopmentandclinicaltranslationofcholecystokinin2receptortargetingradiopharmaceuticals
_version_	1718412769683832832

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

Ejemplares similares